论文部分内容阅读
目的:观察抗胸腺细胞球蛋白(ATG)治疗肾移植术后早期耐激素排斥反应的效果。方法:对34例尸体肾移植术后3d内应用激素冲击治疗期间发生排斥反应的患者以及手术3d后发生耐激素排斥反应的患者采用ATG治疗。结果:其中32例排斥反应得以逆转,肾功能恢复正常,其治愈率为94.1％。2例虽然控制排斥反应,但其肾功能未能恢复,未行移植肾切除。结论:抗胸腺细胞球蛋白(ATG)治疗早期耐激素排斥反应的效果显著,可以使有耐激素排斥反应的肾移植患者获得良好的肾功能。
Objective: To observe the effect of anti-thymocyte globulin (ATG) on early hormone-refractory response after renal transplantation. Methods: 34 patients with rejection after hormone shock therapy were treated with ATG in 34 patients after cadaveric kidney transplantation and patients with hormone rejection after 3d surgery. Results: In 32 cases, the rejection was reversed and the renal function returned to normal. The cure rate was 94.1%. Although two patients controlled rejection, their renal function failed to recover and no allograft was performed. CONCLUSIONS: Anti-thymocyte globulin (ATG) is an effective treatment for early rejection of steroid-induced rejection and can achieve good renal function in renal transplant recipients with hormone-refractory responses.